Skip to content

D&A at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
$2.71M0.0%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$316K-80.4%
TRV
Trevi Therapeutics, Inc.TRVI
$34K-8.1%
Insmed logo
InsmedINSM
$2.08M+64.8%
Mannkind logo
MannkindMNKD
$4.37M+340%

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+236%
Enterprise value$1.19B+224%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's D&A?
Savara (SVRA) reported D&A of $24K in Q1 2026.
How has Savara's D&A changed year-over-year?
Savara's D&A decreased by 20.0% year-over-year, from $30K to $24K.
What is the long-term trend for Savara's D&A?
Over 3 years (2021 to 2024), Savara's D&A has grown at a -1.5% compound annual growth rate (CAGR), from $136K to $130K.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.